Page 5 - Themis Bioscience News Today : Breaking News, Live Updates & Top Stories | Vimarsana

When Merck announced in May that it was a late entrant in the race to develop a COVID-19 vaccine, the American pharmaceutical giant was a popular pick to win.

Drugmaker Merck & Co said on Monday it would stop development of its two COVID-19 vaccines and focus pandemic research on treatments, with initial data on an experimental oral antiviral expected by the end of March.

/PRNewswire/ -- PitchBook, the premier data provider for the private and public equity markets, today released its 2020 Annual European Venture Report, which...

Drugmaker Merck & Co on Monday said it will end development of its two COVID-19 vaccines, and will focus pandemic research on treatments, with initial efficacy data on an experimental oral antiviral expected by the end of March. Merck said in a statement it will record a pretax discontinuation charge in the fourth quarter for vaccine candidate V591, which it acquired with the purchase of Austrian vaccine maker Themis Bioscience, and V590, developed with nonprofit research organization IAVI. In early trials, both vaccines generated immune responses that were inferior to those seen in people wh...

3 Min Read Jan 25 (Reuters) - Drugmaker Merck & Co on Monday said it will end development of its two COVID-19 vaccines, and will focus pandemic research on treatments, with initial efficacy data on an experimental oral antiviral expected by the end of March. Merck said in a statement it will record a pretax discontinuation charge in the fourth quarter for vaccine candidate V591, which it acquired with the purchase of Austrian vaccine maker Themis Bioscience, and V590, developed with nonprofit research organization IAVI. In early trials, both vaccines generated immune responses that were infer...